CAPZB and glioma: Differently, ANXA5 is regarded as a potential early biomarker in hepatocarcinogenesis together with ANXA2 [80] and a predictive biomarker for tumor progression in different cancer types [81], but it was not so far identified as a specific oncogenic protein in gliomas as well as CAPZB and CAPZA1.